Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine

The introduction of new drug classes for migraine, such as monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) or its receptor and small-molecule antagonists of CGRP, have opened a new scenario in a large population of individuals suffering from migraines. The provision of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambat, Fidel Dominique Festin, Bentivegna, Enrico, Martelletti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109201/
https://www.ncbi.nlm.nih.gov/pubmed/35575969
http://dx.doi.org/10.1007/s40259-022-00532-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109201/
https://www.ncbi.nlm.nih.gov/pubmed/35575969
http://dx.doi.org/10.1007/s40259-022-00532-y

Ejemplares similares